The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use

Saudi Pharmaceutical Journal

Volumn 22, Issue 6, 2014, Pages 491-503

  Hassali, Mohamed Azmi ^a   Alrasheedy, Alian A ^a   McLachlan, Andrew ^b   Nguyen, Tuan Anh ^c   AL Tamimi, Saleh Karamah ^a   Ibrahim, Mohamed Izham Mohamed ^d   Aljadhey, Hisham ^e  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d Qatar University ^*  (Qatar)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Generic medicines; Generic policy; Generic substitution; Health system; Pharmacists; Physicians

Indexed keywords

GENERIC DRUG;

AUSTRALIA; COST CONTROL; DRUG COST; DRUG INFORMATION; DRUG PROGRAM; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; EXPERIENCE; FINLAND; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; INTERPERSONAL COMMUNICATION; JAPAN; MALAYSIA; PERCEPTION; PRACTICE GUIDELINE; PRESCRIPTION; REIMBURSEMENT; REVIEW; SWEDEN; THAILAND; UNITED KINGDOM; UNITED STATES;

EID: 84920656236     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2013.12.017     Document Type: Review

References (127)

1. Aalto-Setälä V. The impact of generic substitution on price competition in Finland. Eur. J. Health Econ. 2008, 9:185-191.
2. Al Gedadi N.A., Hassali M.A., Shafie A.A. A pilot survey on perceptions and knowledge of generic medicines among consumers in penaang. Pharm. Pract. 2008, 6:93-97.
3. Alrasheedy A.A., Hassali M.A., Aljadhey H., Ibrahim M.I.M., Al-Tamimi S.K. Is there a need for a formulary of clinically interchangeable medicines to guide generic substitution in Saudi Arabia?. J. Young Pharm. 2013, 5:73-75.
4. Al-Tamimi S.K., Hassali M.A., Alrasheedy A. Challenges to generic medicines utilization in Yemeni healthcare system. GaBI J. 2013, 2.
5. Andersson K., Sonesson C., Petzold M., Carlsten A., Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol. Drug Saf. 2005, 14:341-348.
6. Andersson K., Bergstrom G., Petzold M., Carlsten A. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. Health Policy 2007, 81:376-384.
7. Anonymous (Epilepsy.Com Website), 2007. State laws or statutes governing generic substitution by pharmacists [Online]. Available: (accessed 15 02 2013). http://professionals.epilepsy.com/page/statutes_by_pharmacists.html.
8. Assistant Secretary for Planning and Evaluation (ASPE) U.S. Department of Health and Human Services, Expanding the use of generic drugs [Online]. Available: (accessed 15 02 2013). http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.pdf.
9. Babar Z.-U.D., Awaisu A. Evaluating community pharmacists' perceptions and practices on generic medicines: a pilot study from peninsular Malaysia. J. Generic Med. 2008, 5:315-330.
10. Babar Z.U.D., Ibrahim M.I.M., Singh H., Bukahri N.I., Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007, 4:e82.
11. Beecroft G. Generic drug policy in Australia: a community pharmacy perspective. Aust. New Zealand Health Policy 2007, 4:7.
12. Bobinmyer-Hornecker J.R. Optimizing generic medication use. US Pharm. Generic suppl 2011, 36:22-28.
13. Bongers, F., Carradinha, H., 2009. How to increase patient access to generic medicines in european healthcare systems. EGA Health Economics Committee, European Generic medicines Association.
14. Bulfone L. High prices for generics in australia-more competition might help. Aust Health Rev. 2009, 33:200-214.
15. Bureau of Policy and Strategy. Ministry of Public Health of Thailand, Chapter 14: Creation of universal health security in thailand in: Thailand health profile report 2008-2010 isbn: 978-616-11-1026-0 [Online]. Available: (accessed 23 01 2013). http://www.moph.go.th/ops/thp/images/stories/Report_pics/CD_ROM53/Eng/Chapter14.pdf.
16. Bureau of Policy and Strategy Ministry of Public Health of Thailand, Chapter 6.4: Health expenditure in thailand: Thailand health profile report 2008-2010 isbn: 978-616-11-1026-0 [Online]. Available: (accessed 23 01 2013), 63-64. http://www.moph.go.th/ops/thp/images/stories/Report_pics/CD_ROM53/Eng/Chapter6.4.pdf.
17. Cameron A., Ewen M., Ross-Degnan D., Ball D., Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009, 373:240-249.
18. Cameron A., Mantel-Teeuwisse A.K., Leufkens H.G.M., Laing R.O. Switching from originator brand medicines to generic equivalents in selected developing countries: How much could be saved?. Value Health 2012, 15:664-673.
19. Centre for Product Registration, National Pharmaceutical Control Bureau (NPCB). Ministry of Health Malaysia, Implementation of bioequivalence study for generic medicines in Malaysia [Online]. Available: (accessed 25 01 2013). http://portal.bpfk.gov.my/index.cfm?&menuid=38&parentid=82&highlightid=78.
20. Cha-Oncin S., Yoongthong W., Suwattanapreeda S., Chanjaruporn F. Medicine prices in thailand: a result of no medicine pricing policy. South Med. Rev. 2009, 2:10-14.
21. Chong C.P., Hassali M.A., Bahari M.B., Shafie A.A. Evaluating community pharmacists' perceptions of future generic substitution policy implementation: a national survey from Malaysia. Health Policy 2010, 94:68-75.
22. Chong C.P., Hassali M.A., Bahari M.B., Shafie A.A. Exploring community pharmacists' views on generic medicines: a nationwide study from Malaysia. Int. J. Clin. Pharm. 2011, 33:124-131.
23. Chong C.P., Hassali M.A., Bahari M.B., Shafie A.A. Generic medicine substitution practices among community pharmacists: a nationwide study from Malaysia. J. Public Health 2011, 19:81-90.
24. Chua G.N., Hassali M.A., Shafie A.A., Awaisu A. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy 2010, 95:229-235.
25. Coma A., Zara C., Godman B., Agusti A., Diogene E., Wettermark B., Haycox A. Policies to enhance the efficiency of prescribing in the spanish catalan region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 2009, 9:569-581.
26. Congressional Budget Office (CBO) Congress of the United States, 2010. Effects of using generic drugs on medicare's prescription drug spending [Online]. Available: http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/118xx/doc11838/09-15-prescriptiondrugs.pdf.
27. Coombes R. Gps save £400m in 2008 by increasing use of generic drugs. BMJ 2009, 338.
28. Coster J.M. Trends in generic drug reimbursement in medicaid and medicare. US Pharm. 2010, 35:14-19.
29. Coster J.M. Legislative and regulatory issues affecting generic drug reimbursement. US Pharm. 2012, 37:22-27.
30. Editorial [Lancet].Counterfeit drugs: A growing global threat Lancet 2012, 379:685.
31. Department of Health, 2005a. New long-term arrangements for reimbursement of generic medicines: Scheme M [Online]. Available: (accessed 14 02 2013). http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4114256.pdf.
32. Department of Health, 2005b. New long-term arrangements for reimbursement of generic medicines: Scheme W [Online]. Available: (accessed 14 02 2013). http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4114251.pdf.
33. Department of Health, 2009a. The proposals to implement 'generic substitution' in primary care, further to the pharmaceutical price regulation scheme (PPRS): Response to the consultation [Online]. Available: (accessed 10 01 2013). http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_120433.pdf.
34. Department of Health, 2009b. The proposals to implement 'generic substitution' in primary care, further to the pharmaceutical price regulation scheme (PPRS): Consultation document [Online]. Available: (accessed 10 01 2013). http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_110511.pdf.
35. Department of Health, 2010. Revised long-term arrangements for reimbursement of generic medicines scheme M [Online]. Available: (accessed 14 02 2013). http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_115261.pdf.
36. Department of Health and Aging, 2007. Australian government. Pharmaceutical benefits scheme (PBS) reform [Online]. Available: (accessed 20 01 2013). http://www.health.gov.au/internet/main/publishing.nsf/Content/24693658DD49E286CA2572750081DB74/$File/PBS%20Reform%202Feb07.pdf.
37. Department of Health and Aging, Australian government. About BPS [Online]. Available: (accessed 20 01 2013). http://www.pbs.gov.au/info/about-the-pbs.
38. Department of Health and Aging, 2013. Australian government. Schedule of pharmaceutical benefits [Online]. Available: (accessed 20 01 2013). http://www.pbs.gov.au/publication/schedule/2013/01/2013-01-01-pbs-schedule.pdf.
39. Department of Human Services, 2012. Australian government. PBS reforms [Online]. Available: (accessed 20 01 2013). http://www.medicareaustralia.gov.au/provider/pbs/pharmacists/reforms.jsp.
40. Duerden M.G., Hughes D.A. Generic and therapeutic substitutions in the UK: are they a good thing?. Br. J. Clin. Pharmacol. 2010, 70:335-341.
41. Dylst P., Simoens S. Generic medicine pricing policies in europe: current status and impact. Pharmaceuticals 2010, 3:471-481.
42. Ess S.M., Schneeweiss S., Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003, 21:89-103.
43. Ferner R.E., Lenney W., Marriott J.F. Controversy over generic substitution. BMJ 2010, 340.
44. Generic Pharmaceutical Association GPHA report: Savings trillion over 10years - generic drug savings in the U.S. J. Pharm. Health Ser. Res. 2012, 3:229-236.
45. Godman B., Wettermark B., Hoffmann M., Andersson K., Haycox A., Gustafsson L.L. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoecon Outcomes Res. 2009, 9:65-83.
46. Godman B., Shrank W., Wettermark B., Andersen M., Bishop I., Burkhardt T., Garuolienè K., Kalaba M., Laius O., Joppi R., Sermet C., Schwabe U., Teixeira I., Tulunay F.C., Wendykowska K., Zara C., Gustafsson L.L. Use of generics-a critical cost containment measure for all healthcare professionals in europe?. Pharmaceuticals 2010, 3:2470-2494.
47. Godman B., Shrank W., Andersen M., Berg C., Bishop I., Burkhardt T., Garuoliene K., Herholz H., Joppi R., Kalaba M., Laius O., Mcginn D., Samaluk V., Sermet C., Schwabe U., Teixeira I., Tilson L., Tulunay F.C., Vlahovic-Palcevski V., Wendykowska K., Wettermark B., Zara C., Gustafsson L.L. Comparing policies to enhance prescribing efficiency in europe through increasing generic utilization: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 2010, 10:707-722.
48. Godman B., Wettermark B., Bishop I., Burkhardt T., Fürst J., Garuoliene K. European payer initiatives to reduce prescribing costs through use of generics. GaBI J. 2012, 1:22-27.
49. Godman B., Malmström R., Bennie M., Sakshaug S., Burkhardt T., Campbell S., Garuoliene K., Schwabe U., Vončina L., Gustafsson L.L. Prescribing restrictions-a necessary strategy among some european countries to enhance future prescribing efficiency?. Rev. Health Care 2012, 3:5-16.
50. Godman B., Abuelkhair M., Vitry A., Abdu S., Bennie M., Bishop I. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GaBi J. 2012, 1:21-35.
51. Habl, C., Antony, K., Arts, D., Entleitner, M., Fröschl, B., Leopold, C., Stürzlinger, H., Vogler, S., Weigl, M., 2006 Surveying, assessing and analysing the pharmaceutical sector in the 25 eu member states [Online]. Viena, Austria. Available: (accessed 17 02 2013). http://ec.europa.eu/competition/mergers/studies_reports/oebig.pdf.
52. Hassali M.A., Shafie A.A., Al-Haddad M., Balamurugan T., Awaisu A., Siow Y.L. A qualitative study exploring the impact of the pharmaceutical price war among community pharmacies in the state of Penang, Malaysia. J. Clin. Diagn. Res. 2010, 4:3161-3169.
53. Hassali M.A., Shafie A.A., Chong C.P., Saleem F., Atif M., Chua G., Haq N.U. Community pharmacist's perceptions towards the quality of locally manufactured generic medicines: a descriptive study from Malaysia. J. Appl. Pharm. Sci. 2012, 2(2):56-60.
54. Heikkilä R., Mäntyselkä P., Hartikainen-Herranen K., Ahonen R. Customers' and physicians' opinions of and experiences with generic substitution during the first year in Finland. Health Policy 2007, 82:366-374.
55. Henriksson F., Hjortsberg C., Rehnberg C. Pharmaceutical expenditure in Sweden. Health Policy 1999, 47:125-144.
56. Hoffman J.M., Li E., Doloresco F., Matusiak L., Hunkler R.J., Shah N.D., Vermeulen L.C., Schumock G.T. Projecting future drug expenditures-2012. Am. J. Health Syst. Pharm. 2012, 69:405-421.
57. Hoffman J.M., Li E., Doloresco F., Matusiak L., Hunkler R.J., Shah N.D., Vermeulen L.C., Schumock G.T. Projecting future drug expenditures in u.S. Nonfederal hospitals and clinics-2013. Am. J. Health-Syst. Pharm. 2013, 70(6):525-539.
58. Huskamp H.A., Deverka P.A., Epstein A.M., Epstein R.S., Mcguigan K.A., Frank R.G. The effect of incentive-based formularies on prescription-drug utilization and spending. N. Engl. J. Med. 2003, 349:2224-2232.
59. Iizuka T. Generic entry in a regulated pharmaceutical market. Jpn. Econ. Rev. 2009, 60:63-81.
60. Joint Formulary Committee, 2011. British national formulary, London, BMJ Group and Pharmaceutical Press.
61. Kanavos P. Do generics offer significant savings to the uk national health service?. Curr. Med. Res. Opin. 2007, 23:105-116.
62. Kaojarern S., Pattanaprateep O. The effect of introducing inpatient mandatory generic drug substitution at ramathobodi hospital. J. Med. Assoc. Thailand =Chotmaihet Thangphaet 2012, 95:519-525.
63. Kaplan W.A., Ritz L.S., Vitello M., Wirtz V.J. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 2012, 106:211-224.
64. Keenum A.J., Devoe J.E., Chisolm D.J., Wallace L.S. Generic medications for you, but brand-name medications for me. Res. Social Adm. Pharm. 2012, 8:574-578.
65. Kobayashi E., Karigome H., Sakurada T., Satoh N., Ueda S. Patients' attitudes towards generic drug substitution in japan. Health Policy 2011, 99:60-65.
66. Kobayashi E., Satoh N., Ueda S. Community pharmacists' perspectives on generic substitution in japan. J. Public Health 2011, 19:249-256.
67. Kohl S.H., Shrank W.H. Increasing generic drug use in medicare part d: the role of government. J. Am. Geriatr. Soc. 2007, 55:1106-1109.
68. Leng C.B., Ibrahim M.I.M., Shafie A.A., Bahri S. Medicines spending trends in a Malaysian public hospital. J. Pharm. Pract. Res. 2011, 41. 250-250.
69. Lofgren H. Generic drugs: international trends and policy developments in australia. Aust. Health Rev. 2004, 27:39-48.
70. Lofgren H. Generic medicines in australia: business dynamics and recent policy reform South. Med. Rev. 2009, 2:24-28.
71. Martikainen J., Rajaniemi S. Drug reimbursement systems in eu member states, iceland and norway. Helsinki: The social insurance institution of Finland. Soc. sec. Health Rep. 2002, 54:36.
72. Matin Y. Scrip's complete guide to the world generic drugs market 1999, PJB Publications Ltd, Richmond (UK).
73. Ministry of Finance of Japan, Cost of pharmaceuticals.
74. Ministry of Health Labour and Welfare of Japan (MHLW), 2012a. Policy report: Promotion of the use of generic drugs [Online]. Available: (accessed 20 01 2013). http://www.mhlw.go.jp/english/policy_report/2012/09/120921.html.
75. Ministry of Health Labour and Welfare of Japan, 2012b. An outline of the japanese medical system [Online]. Available: (accessed 20 01 2013). http://www.mhlw.go.jp/bunya/iryouhoken/iryouhoken01/dl/01_eng.pdf.
76. Ministry of Health Malaysia, 2009. Malaysian national medicines policy. 2nd edition [Online]. Available: http://pharmacy.gov.my/aeimages//File/MNMP_DUNAS.pdf.
77. Ministry of Health Malaysia. National Pharmaceutical Control Bureau, Information on bioequivalence (BE) [Online]. Available: (accessed 15 01 2013). http://portal.bpfk.gov.my/index.cfm?&menuid=38&parentid=82&highlightid=78.
78. Mott D.A., Cline R.R. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med. Care 2002, 40:662-674.
79. National Pharmaceutical Control Bureau (NPCB). Ministry of Health Malaysia, Generic product list for bioequivalence studies [Online]. Available: (accessed 15 01 2013). http://portal.bpfk.gov.my/index.cfm?&menuid=14&parentid=82&highlightid=78.
80. National Pharmaceutical Control Bureau (NPCB). Ministry of Health Malaysia, 2013. Drug registration guidance document (DRGD). 1st edition [Online]. Available: (accessed 15 01 2013). http://portal.bpfk.gov.my/aeimages//File/Complete_DRGD_with_appendices_updated.pdf.
81. National Prescribing Service Limited (NPS), 2012. Medicine brand choices [Online]. Available: (accessed 20 01 2013). http://www.nps.org.au/conditions-and-topics/topics/campaigns-events/brand-choices.
82. Neuman P., Cubanski J. Medicare part d update-lessons learned and unfinished business. N. Engl. J. Med. 2009, 361:406-414.
83. Organisation for Economic Co-Operation and Development (OECD), 2008. Pharmaceutical pricing policies in a global market [Online]. Available: (accessed 16 02 2013). http://apps.who.int/medicinedocs/documents/s19834en/s19834en.pdf.
84. Office of Fair Trading (OFT), 2007. Annexe A: Markets for prescription pharmaceuticals in the nhs [Online]. Available: (accessed 16 02 2013). http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885a.pdf.
85. PBS Information Management Section, 2012. Pharmaceutical policy branch. Department of health and ageing. Expenditure and prescriptions twelve months to 30 06 2012 [Online]. Available: http://www.pbs.gov.au/statistics/2011-2012-files/expenditure-and-prescriptions-2011-2012.pdf.
86. Pharmaceutical Benefits Board (LFN), 2007. The swedish pharmaceutical reimbursement system - a brief overview [Online]. Available: (accessed 10 01 2013). http://www.tlv.se/Upload/English/ENG-swe-pharma-reimbursement-system.pdf.
87. Ping C.C., Bahari M.B., Hassali M.A. A pilot study on generic medicine substitution practices among community pharmacists in the state of Penang, Malaysia. Pharmacoepidemiol. Drug Saf. 2008, 17:82-89.
88. Plianbangchang P., Jetiyanon K., Suttaloung C., Khumchuen L. Physicians' generic drug prescribing behavior in district hospitals: a case of phitsanulok, thailand. Pharm. Pract. (Internet) 2010, 8:167-172.
89. Saudi Ministry of Health (MOH), 2008. Statistics book year 2008.(in arabic) [Online]. Available: (Accessed 3 02 2013). http://www.moh.gov.sa/statistics/index.html.
90. Schneeweiss S., Walker A.M., Glynn R.J., Maclure M., Dormuth C., Soumerai S.B. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N. Engl. J. Med. 2002, 346:822-829.
91. Sermet C., Andrieu V., Godman B., Van Ganse E., Haycox A., Reynier J.-P. Ongoing pharmaceutical reforms in france. Appl. Health Econ. Health Policy 2010, 8:7-24.
92. Shafie A.A., Hassali M.A. Price comparison between innovator and generic medicines sold by community pharmacies in the state of Penang, Malaysia. J. Generic Med. 2008, 6:35-42.
93. Sharrad A.K., Hassali M.A., Shafie A.A. Generic medicines perceptions of physicians in basrah, iraq. Austr. Med. J. 2009, 1:58-64.
94. Sheppard, A., 2011 Generic medicines: Essential contributors to the long-term health of society. Ims health. [Online]. Available: (accessed 4 02 2013). http://www.imshealth.com/imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_GA.pdf.
95. Shrank W.H., Hoang T., Ettner S.L., Glassman P.A., Nair K., Delapp D., Dirstine J., Avorn J., Asch S.M. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch. Intern. Med. 2006, 166:332.
96. Shrank W.H., Stedman M., Ettner S.L., Delapp D., Dirstine J., Brookhart M.A., Fischer M.A., Avorn J., Asch S.M. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. J. Gen. Intern. Med. 2007, 22:1298-1304.
97. Shrank W.H., Cox E.R., Fischer M.A., Mehta J., Choudhry N.K. Patients' perceptions of generic medications. Health Aff. 2009, 28:546-556.
98. Shrank W.H., Choudhry N.K., Agnew-Blais J., Federman A.D., Liberman J.N., Liu J., Kesselheim A.S., Brookhart M.A., Fischer M.A. State generic substitution laws can lower drug outlays under medicaid. Health Aff. 2010, 29:1383-1390.
99. Shrank W.H., Liberman J.N., Fischer M.A., Girdish C., Brennan T.A., Choudhry N.K. Physician perceptions about generic drugs. Ann. Pharmacother. 2011, 45:31-38.
100. Simoens S. Developing the Japanese generic medicines market: what can we learn from Europe?. J. Generic Med. 2009, 6:129-135.
101. Simoens S. Creating sustainable european health-care systems through the increased use of generic medicines: A policy analysis. Journal of Generic Medicines 2010, 7:131-137.
102. Simoens S. A review of generic medicine pricing in europe. GaBI J. 2012, 1:8-12.
103. Simoens, S., Coster, S. D., 2006. Sustaining generic medicines markets in europe [Online]. Belgium. Available: (accessed 15 02 2013). http://212.85.101.126/images/publikacje/7_pl.pdf.
104. Simoens S., De Coster S. Sustaining generic medicines markets in Europe. J. Generic Med. 2006, 3:257-268.
105. Steinman M.A., Chren M.-M., Landefeld C.S. What's in a name? Use of brand versus generic drug names in united states outpatient practice. J. Gen. Intern. Med. 2007, 22:645-648.
106. Sturm H., Austvoll-Dahlgren A., Aaserud M., Oxman A., Ramsay C., Vernby A., Kösters J. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst. Rev. 2007, 3.
107. Sukontharat, B., Udom, P., Kulchandee, S., Topark-Ngarm, A., Evaluating pharmacists' perception on generic substitution. The 4th annual northeast pharmacy research conference of 2012 "pharmacy profession in harmony". Faculty of pharmaceutical sciences, khon kaen university, Thailand february 11 - 12, 2012.
108. The Association of the British Pharmaceutical Industry (ABPI), Generic medicines [Online]. Available: (accessed 15 02 2013). http://www.kidney.org.uk/main/switch_meds/generic.pdf.
109. The Centre for Strategic Economic Studies (CSES). Victoria University. Australia, 2009. Impact of pbs reforms on pbs expenditure and savings [Online]. Available: (accessed 20 01 2013). http://medicinesaustralia.com.au/files/2010/02/The-impact-of-PBS-reforms-on-PBS-expenditure-and-savings.pdf.
110. The Finnish Medicines Agency (Fimea), 2013. Interchangeable drug list [Online]. Available: (accessed 10 01 2013). http://www.fimea.fi/medicines/substitutable_medicinal_products.
111. The Social Insurance Institution of Finland (KELA), 2009. Generic substitution generated nearly € 40 million of savings in Finland in six months [Online]. Available: (accessed 10 01 2013). http://www.kela.fi/in/internet/english.nsf/NET/181103105045MP?OpenDocument.
112. The Swedish Medical Products Agency (MPA), 2010. The list of substitutable medicinal products [Online]. Available: (accessed 10 01 2013). http://www.lakemedelsverket.se/english/product/Medicinal-products/Substitution/.
113. The U.S. Department of Health and Human Services-FDA/CDER, 2012. Office of generic drugs. Orange book: Approved drug products with therapeutic equivalence evaluations [Online]. Available: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf.
114. The US Food and Drug Administration (FDA), 2009. FDA center for drug evaluation and research. Office of generic drugs. What are generic drugs? [Online]. Available: (accessed 10 01 2013). http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm144456.htm.
115. The US Food and Drug Administration (FDA), 2012. FDA center for drug evaluation and research. Office of generic drugs. Facts about generic drugs [Online]. Available: (accessed 10 01 2013). http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm167991.htm.
116. The US Food and Drug Authority (FDA), 2010. Generic competition and drug prices [Online]. Available: (accessed 2 02 2013). http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129385.htm.
117. Thomas R., Vitry A. Consumers' perception of generic medicines in community pharmacies in Malaysia. South Med. Rev. 2009, 2:20-23.
118. Vivian J.C. Generic-substitution laws. US Pharm. Generic Drug Rev. 2008, 3:30-34.
119. Vogler, S., Schmickl, B., 2010. Rational use of generic medicines in europe [Online]. Österreichisches Bundesinstitut für Gesundheitswesen (ÖBIG). Vienna, Austria. Available: (accessed 15 01 2013). http://ppri.oebig.at/Downloads/Publications/RationalUseOfMedicinesEurope_ExSummary.pdf.
120. Wettermark B., Godman B., Andersson K., Gustafsson L.L., Haycox A., Bertele V. Recent national and regional drug reforms in Sweden: Implications for pharmaceutical companies in europe. Pharmacoeconomics 2008, 26:537-550.
121. World Health Organization (WHO), 2003. How to develop and implement a national drug policy [Online]. Available: (accessed 12 2012). http://apps.who.int/medicinedocs/en/d/Js2283e/.
122. World Health Organization (WHO), 2004. The world medicines situation. Geneva, swizerland: World Health Organization.
123. World Health Organization (WHO), 2011. The world medicines situation: Access to essential medicines as part of the right to health. In: Hogerzeil, H. V. & Mirza, Z. (eds.). Geneva: World Health Organization.
124. World Health Organization (WHO), 2012. Glossary of globalization, trade and health terms [Online]. Available: (accessed 12 2012]. http://www.who.int/trade/glossary/story034/en/index.html.
125. World Health Organization/Health Action International (WHO/HAI), 2006. Thailand: Medicine prices, availability, affordability and price components. Geneva. WHO and HAI [Online]. Available: http://www.haiweb.org/medicineprices/surveys/200610TH/sdocs/Thailand-summary-report-FINAL.pdf.
126. World Health Organization/Health Action International (WHO/HAI), 2011 Project on medicine prices and availability review series on pharmaceutical pricing policies and interventions working paper 2: The role of health insurance in the cost-effective use of medicines 2011 [Online]. Available: (accessed 23 01 2013). http://www.haiweb.org/medicineprices/24072012/HealthinsurancefinalMay2011.pdf.
127. Zuvekas S.H., Cohen J.W. Prescription drugs and the changing concentration of health care expenditures. Health Aff. 2007, 26:249-257.